Daiichi reports mixed Phase III data for pain candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported mixed data from four Phase III trials of mirogabalin (DS-5565) to treat postherpetic neuralgia (PHN) and pain associated with fibromyalgia.

In the Asian Phase III NEUCOURSE trial in 765 patients with PHN, mirogabalin met the primary endpoint of reducing weekly average daily pain score from baseline to week 14 vs. placebo...